ReviewWorld journal of gastroenterology2014
Cirrhosis and hepatopulmonary syndrome.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 51 citations in OpenAlex.
- Successful Treatment of Severe Hepatopulmonary Syndrome as a Rare Complication of Zellweger Spectrum Disorder.JIMD reports · 2025Article
- Overcoming Intrapulmonary Shunting: A Case Report of Hepatopulmonary Syndrome Post-Liver Transplantation Treated With Inhaled Treprostinil.Respirology case reports · 2025Article
- Review
- The effects of N-acetylcysteine on hepatic, hematologic, and renal parameters in cirrhotic patients: a randomized controlled trial.Gastroenterology and hepatology from bed to bench · 2023Article
- Liver cirrhosis and complications from the perspective of dysbiosis.Frontiers in medicine · 2023Review
- Impact of Liver Transplantation on Carbon Monoxide Production as Measured by Arterial Carboxyhemoglobin Levels in Cirrhotic Patients with and without Hepatopulmonary Syndrome.Annals of transplantation · 2021Article
- Portal Venous Flow Is Increased by Jejunal but Not Colonic Hydrogen Sulfide in a Nitric Oxide-Dependent Fashion in Rats.Digestive diseases and sciences · 2021Article
- When common things aren't so common: A case report of hepatopulmonary syndrome.Clinical medicine (London, England) · 2021Article
- Pulmonary Complications in Candidates for Liver Transplantation.Middle East journal of digestive diseases · 2020Review
- Impact of liver damage on blood-borne variables and pulmonary hemodynamic responses to hypoxia and hyperoxia in anesthetized rats.BMC cardiovascular disorders · 2020Article
- Vascular syndromes in liver cirrhosis.Clinical journal of gastroenterology · 2019Review
- Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study.Digestive diseases and sciences · 2018Observational
- Rifaximin has the potential to prevent complications of cirrhosis.Therapeutic advances in gastroenterology · 2018Article
- Hepatopulmonary syndrome: What we know and what we would like to know.World journal of gastroenterology · 2016Review
- Dexmedetomidine Attenuates Bilirubin-Induced Lung Alveolar Epithelial Cell Death In Vitro and In Vivo.Critical care medicine · 2015Article
- Overview of Complications in Cirrhosis.Journal of clinical and experimental hepatologyReview
- Cardiovascular dysfunction in patients with liver cirrhosis.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatopulmonary syndrome (HPS) is characterized as a triad: liver disease, intrapulmonary vascular dilatation and arterial hypoxemia. HPS is reported to be present in 4% to 32% of adult patients with end-stage liver disease and in 9%-20% of children. The pathogenesis of HPS has not been clearly identified. Portal hypertension causes impairment in the perfusion of the bowel and increases the enteral translocation of Gram (-) bacteria and endotoxins. This stimulates the release of vasoactive mediators, such as tumor necrosis factor-alpha, heme oxygenase-derived carbon monoxide and nitric oxide. Genetic alterations have not been associated with this syndrome yet; however, cytokines and chemokines have been suggested to play a role. Recently, it was reported that cumulated monocytes lead to the activation of vascular endothelial growth factor-dependent signaling pathways and pulmonary angiogenesis, which plays an important role in HPS pathogenesis. At present, the most effective and only radical treatment is a liver transplant (LT). Cirrhotic patients who are on the waiting list for an LT have a shorter survival period if they develop HPS. Therefore, it is suggested that all cirrhotic cases should be followed closely for HPS and they should have priority in the waiting list.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.